Chuangyebang was informed that recently, Jinan Microscopic Intelligent Technology Co., Ltd. (hereinafter referred to as: Microscopic Intelligence), a leading special optical imaging company in China, completed a pre-A+ round of financing of tens of millions of yuan, led by Linglong Fund, October Capital follow-up. This round of financing will continue to be used for the company’s new product research and development registration and market academic promotion.
Micro-Intelligence was established in Jinan, Shandong on June 29, 2017. After five years of rapid development, it has established R&D centers and production centers in Hangzhou, Zhejiang and Liuyang, Hunan respectively. Jingtexin” and the recognition of high-tech enterprises in Hunan Province. In order to realize the international strategic layout in the company’s “second five-year” development plan, the company has signed a contract with the Shanghai G60 Science and Technology Cloud Gallery, and the relocation of the relevant headquarters is being carried out in an orderly manner.
Microsmart has the world’s leading special light imaging technology platform, and has obtained more than 30 patents, and the number of patent searches in the sub-sector is the top three in the world. The company’s original research and development of picomolar ultra-high-sensitivity image detectors are world-leading, and have the world’s fifth invention patent for fluorescent contrast agents. At present, a number of products of the company have been successfully commercialized, covering thyroid surgery, breast surgery, hepatobiliary surgery, thoracic surgery, gastrointestinal surgery, gynecology and other departments, and have constructed a commercial closed loop of “equipment + consumables”. Among them, products such as parathyroid imaging system and triple tracer fluorescence endoscopy system are the first in China. Microsmart is also one of the few companies in the world that can master autofluorescence imaging technology and successfully commercialize it.
Micro-Intelligence has successively received angel round investment from Luxin Venture Capital and pre-A round investment from GT Venture Capital and Zhenghai Investment. After this round of financing, the company plans to officially open the Series A financing in July.
Regarding this financing, Yang Cong, founder of Microsmart, said: “In the first half of the year, the company forged ahead under the severe and complicated situation of the new crown epidemic in the country, and obtained three Class II registration certificates as scheduled, achieved the expected business goals and finally completed the This round of financing is inseparable from the strong support of new and old investors to the company and the professional and pragmatic working attitude of the company team, as well as the care and help of friends from all walks of life, including park leaders and hospital experts, for the company.”
Zhang Jun, chairman of Linglong Fund, said: “Special light imaging technology is one of the most promising tracks in the medical device field in recent years, and it is also the company’s key focus. Microscopic intelligence is based on the underlying breakthrough of special light imaging technology. It has successfully commercialized a number of domestic and even international leading products, completed the product layout of multiple departments such as thyroid and breast surgery, hepatobiliary surgery, and thoracic surgery, and completed academic and market cooperation with more than 100 tertiary hospitals. During the epidemic, the company is still on schedule Completed the registration of several core products and achieved sales results that meet expectations, which fully reflects the company’s team’s entrepreneurial spirit and excellent business capabilities. It is an honor to participate in this round of financing of Microsmart Join hands with the company to jointly build a leading brand in the field of special light imaging.”
Gong Hanting, a partner of October Capital, said: “Microsmart is an excellent R&D enterprise in the field of special light imaging in China, especially in the field of autofluorescence. Based on the deep technical accumulation in this field, the company has formed a product pipeline with distinctive features and solved the relevant problems. The pain points in the surgical operation have improved the quality of life of patients after surgery. We are very fortunate to be able to participate in this financing of Microsmart, and in the future we will continue to support companies using core technologies to develop more innovative products that meet clinical needs.”
media coverage
The investment community Yiou Venture State
Related events
- Microsmart completed the Pre-A+ round of financing, led by Linglong Fund2022-06-29
- Billion Medical completed a new round of financing of 100 million yuan2021-08-06
This article is reprinted from: https://readhub.cn/topic/8heAOXUwkuN
This site is for inclusion only, and the copyright belongs to the original author.